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Recent studies indicated nm23-H1 played a role in cancer progression. Therefore, we investigated clinical significance of nm23-H1
expression in oral squamous cell carcinoma (OSCC). In total, 86 OSCC specimens were immunohistochemically stained with nm23-
H1-specific monoclonal antibodies. Immunohistochemical staining of nm23-H1 was confirmed by immunoblotting. The relations
between nm23-H1 expression and clinicopathologic variables were evaluated by w
2 analysis. As increased size of primary tumour
could escalate metastatic potential and the data of patients at the late T stage might confound statistical analyses, we thus paid special
attention to 54 patients at the early T stage of OSCC. Statistical difference of survival was compared by a log-rank test.
Immunohistochemically, nm23-H1 expression was detected in 48.8% (42 out of 86) of tumorous specimens. It positively correlated
with larger primary tumour size (P¼0.03) and inversely with cigarette-smoking habit (P¼0.042). In patients at the early T stage,
decreased nm23 expression was associated with increased incidence of lymph node metastasis (P¼0.004) and indicated poor
survival (P¼0.014). Tumour nm23-H1 expression is a prognostic factor for predicting better survival in OSCC patients at the early T
stage, which may reflect antimetastatic potential of nm23. Therefore, modulation of nm23-H1 expression in cancer cells can provide
a novel possibility of improving therapeutic strategy at this stage. In addition, our results further indicated cigarette smoking could
aggravate the extent of nm23-H1 expression and possibly disease progression of OSCC patients.
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Oral squamous cell carcinoma (OSCC) is the most common
malignant tumour of the oral cavity. The incidence of OSCC differs
among the various regions of the world and the relative frequency
ranges from less than 0.1% to over 40% (Pindborg, 1977;
Sankaranarayanan, 1990). In Taiwan, OSCC constitutes a sig-
nificant portion of all malignancies (Tsay and Chiu, 1990). Since
1991, this disease has been the fifth leading cause of cancer death
in males, and the seventh in the whole population (Hsieh et al,
2001).
Despite the curative surgical resection and multitherapeutic
modalities, the overall survival has not improved substantially in
the last two decades (Zakrzewska, 1999). The major causes of
treatment failure are early lymphatic involvement and distant
metastasis. It has been reported that more than half of the patients
with resectable OSCC had locoregional spreading at diagnosis
(Chen et al, 1999; Wang et al, 2002). Moreover, the differential
responses between patients with a small oral tumour but evident
metastasis having poorer prognosis and those with a large primary
lesion but without detectable spreading obtaining better survival
suggest a basic mechanism underlying this difference. A biomarker
that can reflect this mechanism, forecast the status of disease
progression and the potential of cancer metastasis would be
imperative to commence the optimal treatment and improve
survival significantly.
The nm23 gene was originally identified by differentiating cDNA
libraries from strongly and weakly metastatic murine melanoma
cell lines (Steeg et al, 1988a). Higher expression of nm23 was found
in weakly metastatic cells. Further studies confirmed the
antimetastatic effect in animal models (Steeg et al, 1988b; Caligo
et al, 1992) and in human carcinomas (Bevilacqua et al, 1989;
Caligo et al, 1997). The consequent protein analysis showed that
nm23 not only had the sequence homologous to nucleoside
diphosphate kinase (NDPK) but also had NDPK activity to convert
nucleoside diphosphates to nucleoside triphosphates with an
expense of ATP (Gilles et al, 1991; Cipollini et al, 1997). In
human, nm23/NDPK family consists of at least eight homologues
(nm23-H1 to nm23-H8) (Lacombe et al, 2000). Among these
homologues, nm23-H1 and nm23-H2, sharing an 88% identity with
each other, are further shown closely associated with antimeta-
static potential (Stahl et al, 1991). Nonetheless, clinical studies of
nm23 expression in various cancers did not fully support such
notion. A few clinical results indeed indicated that nm23
expression, as anticipated from the in vitro investigations,
correlated with better prognosis (Bevilacqua et al, 1989; Barnes
et al, 1991; Hirayama et al, 1991; Nakayama et al, 1992; Campo
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yet al, 1994; Hsu et al, 1999). Results from other studies, on the
contrary, suggested that nm23 might facilitate tumour develop-
ment and disease progression (Hailat et al, 1991; Zou et al, 1993;
Mu ¨ller et al, 1998; Pavelic et al, 2000). The discrepancy may be due
to, in part, the difference of study design and, in part, study end
point selected. It is worth noting that tumour development is a
multifactorial process, and it is likely that a specific factor might be
able to play a certain role only within a defined period of disease
progression. At other time, the nature of this specific factor might
change.
Expression of nm23 and its clincopathologic significance have
not been well established in patients with OSCC. Therefore, in this
study, we used immunohistochemical (IHC) method to examine
the nm23-H1 expression in surgical specimens of OSCC patients.
Expression of nm23-H1 was further confirmed by immunoblot-
ting. Correlations between nm23-H1 and respective clinicopatho-
logic parameters as well as prognostic significance of nm23-H1 in
OSCC patients were assessed by statistical analysis, in which nm23
expression was used as the determinant to categorise the
functional groups. The biological role of nm23-H1 in OSCC was
then deduced following these analyses.
MATERIALS AND METHODS
Patients and tissue specimens
From October 1984 to June 1998, clinicopathologic data and tissue
specimens from 86 consecutive patients diagnosed as OSCC were
collected. All patients were pathologically confirmed OSCC. The
preoperative workup consisted of physical examination, intraoral
biopsy, computed tomography (CT) scan of head and neck,
sonography of the abdomen, chest radiography and radioisotopic
bone scan of whole body. All patients underwent surgical resection
of tumours. Comprehensive or selective neck dissection was
performed for suspected cervical lymphadenopathy or prophylac-
tic neck management (Scully and Porter, 2000). Local irradiation
and/or systemic cisplatin-based chemotherapy were postopera-
tively administered for patients with advanced stages of the
disease, insufficient margins (o2cm) of curative resection or
tumour recurrence. Nevertheless, no patient received neoadjuvant
therapy in this cohort. After treatment, all patients were followed
routinely. Stages of the disease were categorised based on TNM
staging system (Fleming et al, 1997). According to Broders’ criteria
(Anneroth et al, 1987), differentiation pattern of the malignancy
was classified into three histologic grades: well, moderately and
poorly differentiated squamous cell carcinoma. Of 86 surgical
specimens, 50 were well and 36 were moderately differentiated
carcinomas. No poorly differentiated OSCC was detected. Tumour
recurrence and metastasis were identified when physical examina-
tion, endoscopy, chest radiography, CT scan of head and neck,
sonography of the abdomen or radioisotopic bone scan of whole
body showed an evidence. If possible, biopsy confirmation was
performed. Medical Ethical Committee has approved this protocol
and the written informed consent has been obtained from every
patient before surgery. A single-blinded procedure was followed
for immunohistochemical staining, immunoblotting and statistical
analysis.
Immunohistochemical staining
Expression of nm23-H1 in the pathologic sections was detected by
an immunoperoxidase method as previously described (Wang et al,
1999a,2002). Paraffin blocks were sectioned at the thickness of
4mm. The wax was melted at 651C overnight. The sections were
deparaffinised in xylene, and xylene was subsequently removed
with absolute ethanol. The slides were then incubated with mouse
monoclonal antibodies specific to nm23-H1 (Santa Cruz Biotech-
nology, CA, USA) and followed by biotin-conjugated goat anti-
mouse immunoglobulin and horseradish peroxidase (HRP)-con-
jugated streptavidin (DAKO, Glostrup, Denmark). Aminoethylcar-
bazole was used as chromogenic substrate and red precipitate was
identified as positive staining. The specimens were counterstained
with haematoxylin and mounted with glycerol gelatin. In each
experiment, a section of human breast cancer known to over-
express nm23-H1 was served as a positive control (DAKO,
Glostrup, Denmark) and a section without adding the primary
antibody was used as a negative control. Each batch of IHC
contained the slides of a positive and a negative control to ensure
the staining quality.
Slide evaluation of immunohistochemical staining
Slide evaluation has been described previously (Barnes et al, 1991;
Hsu et al, 1999). Briefly, histologically nontumourous epithelium
of oral tissue was served as internal negative control in each case.
Under the low-power field, each slide was evaluated randomly at
10 different areas containing tumour cells by two independent
investigators blinded to the clinicopathologic data. At least 100
tumour cells were examined per field. Two scoring systems,
staining intensity and percentage of stained cells, were included in
our study (Barnes et al, 1991; Moskaluk, 2002). The staining
intensity was scored on a semiquantitative four-point scale as
follows: 0, equivalent to the negative control; 1, weak cytoplasmic
stain slightly darker than the negative control; 2, moderate stain
defined as the intensity between score 1 and 3; 3, intense stain
equivalent to or darker than the positive control. We use the
photomicrographs of the respective four scales (0–3) as standard
comparators while interpreting the slides. When there were more
than 25% of cancer cells with staining intensity scored above 2–3
(Figure 1), nm23-H1 expression was recorded positive for this
patient (Wang et al, 1999b).
Immunoblotting
IHC staining of nm23-H1 was then confirmed by immunoblotting
in part of surgical specimens. Briefly, tissues were washed in
phosphate-buffered saline and lysed in loading buffer containing
50mM Tris (pH 6.8), 150mM NaCl, 1mM disodium EDTA, 5% b-
mercaptoethanol, 1mM phenylmethylsulphonylfluoride, 0.01%
bromophenol blue, 10% glycerol and 1% SDS supplemented with
Figure 1 Immunohistochemical staining for nm23-H1 protein in OSCC.
Left: Representative example of positive nm23-H1 expression, which
demonstrated intense nm23-H1 immunoreactivity (arrows) in the
cytoplasma of tumour cells. Right: Representative example of negative
nm23-H1 expression. Arrowhead indicates almost no precipitate in the
cytoplasma of tumour cells (original magnification  400).
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yleupeptin (10mgml
 1), aprotinin (10mgml
 1) and trypsin inhi-
bitor (10mgml
 1). Electrophoresis was carried out in 12%
polyacrylamide gel with 4.5% stacking gel. After electrophoresis,
proteins were transferred to a nitrocellulose membrane. The
membrane was then probed with mouse monoclonal antibodies
specific to nm23-H1 (1:500), and then HRP-conjugated goat anti-
mouse IgG (ICN Pharmaceuticals, OH, USA) (1:5000). The protein
bands were visualised by exposing a X-Omat film (Eastman Kodak,
NY, USA) with enhanced chemiluminescent reagent (PIERCE, IL,
USA) to the membrane.
Statistical analysis
The relationships between nm23-H1 expression and each of
clinicopathologic parameters, including histologic grade of malig-
nancy, primary tumour size, lymph node involvement, distant
metastasis, tumour recurrence, habits of betel nut-chewing and
cigarette-smoking, were analysed by w
2 with Yates’ correction or
Fisher’s exact test (when the expected number of any cell was fewer
than five). Survival curves were plotted with the method of
Kaplan–Meier (Kaplan and Meier, 1958). Statistical difference of
survival between different groups was compared by a log-rank test
(Peto and Pike, 1973). The joint effect of clinicopathologic factors
was further tested in multivariate analysis using a Cox regression
model (Peto and Pike, 1973). Statistical analysis was performed by
using SPSS software (version 10.0, SPSS Inc., IL, USA). Statistical
significance was set at P-value o0.05.
RESULTS
Clinicopathologic characteristics
The mean age of this study group was 49.7 years (range, 24–85
years) and male–female ratio was 5.6:1 (73 men and 13 women).
The median follow-up was 35.5 months, ranging from 1 to 165
months. Up to the time of final statistical analysis, 49 of 86 patients
(57%) were well and alive. However, 35 patients died of OSCC
carcinomatosis and two deaths were OSCC-unrelated. Therefore,
only 84 patients’ data were legitimate for survival analysis. The
overall cumulative 1-, 3- and 5-year survival rates were 83, 66 and
56%, respectively.
Expression of nm23-H1
Immunohistochemically, nm23-H1 was detected in 48.8%. (42 of
86) of tumourous specimens. IHC staining for nm23-Hl was
predominantly cytoplasmic (Figure 1). To further confirm the
nm23-Hl expression in OSCC, immunoblotting was carried out to
compare 10 pairs of tumourous and nontumourous counterparts.
The result was shown in Figure 2 and nm23-H1 was indicated as a
23-kDa band.
Relationships between nm23-Hl expression and
clinicopathologic variables
Relationships between nm23-Hl expression and seven respective
clinicopathologic variables, for example, histologic grade of
malignancy, tumour size, lymph node involvement, distant
metastasis, tumour recurrence, habits of betel nut-chewing and
cigarette-smoking, were summarised in Table 1. The nm23
expression correlated only with two clinicopathologic variables:
tumour size and cigarette-smoking habit. In 65.6% (21 out of 32)
of patients with larger-size primary tumours (44cm), while only
in 38.9% (21out of 54) of those with smaller-size tumours (p4cm)
were nm23-Hl positive (P¼0.03). Moreover, in patients with
cigarette-smoking habit, nm23-Hl positive rate (68%, 17out of 25)
was lower than those without this habit (41%, 25 out of 61) and the
difference was significant (P¼0.042). Although fewer patients with
nm23-Hl-positive OSCCs had cervical lymph node involvement
(37.2 vs 62.8%) or distant metastasis (23.1 vs 76.9%) than those
with nm23-H1-negative tumours, these differences were marginal
(P¼0.052 and 0.086, respectively). Nonetheless, nm23-Hl expres-
sion did not correlate with histologic grade of malignancy, tumour
recurrence or betel nut-chewing habit.
Effect evaluation of nm23-Hl in 54 OSCC patients at the
early T stage
When we analysed the data only from patients at the early T stages
(tumour size p4cm), our results showed that the incidence of
cervical lymph node involvement was indeed higher in the nm23-
Hl negative group (51.5%, 17 out of 33) than the nm23-Hl positive
group (9.5%, two out of 21) and the difference was statistically
significant (P¼0.004). Moreover, cigarette-smoking habit re-
mained as a significant factor for suppressing nm23-Hl expression
(P¼0.022) (Table 2). Otherwise, no significant correlation was
found between nm23-Hl expression and the other clinicopatholo-
gic factors, for example, histologic grade, tumour recurrence,
distant metastasis and betel nut-chewing habit.
Survival analysis of 84 OSCC patients
When all patients were divided into groups by each of clinico-
pathologic factors, significant difference by univariate analysis was
shown in the following factors: tumour size (Po0.001), lymph node
involvement (Po0.001), distant metastasis (Po0.001), and tumour
recurrence (Po0.001) (Table 3). In multivariate analysis, only
tumour size (P¼0.002), distant metastasis (Po0.001) and tumour
recurrence (P¼0.040) remained significant. No statistical difference
was found in histologic grade of malignancy, habits of betel nut-
chewing and cigarette-smoking, or nm23-H1 expression.
Survival analysis of 53 OSCC patients at the early T stage
When we analysed the data only from patients at the early T stages,
statistical differences were found between survivals of two groups
categorised by nm23-H1 expression (P¼0.014) (Figure 3) and
cigarette-smoking habit (P¼0.032), in addition to lymph node
involvement (P¼0.015), distant metastasis (Po0.001) and tumour
recurrence (P¼0.003). Nonetheless, in the multivariate analysis,
only distant metastasis correlated with poor prognosis (P¼0.013).
The results are summarised in Table 4.
DISCUSSION
Our results demonstrated that decreased nm23 expression in
OSCC patients might correlate with tumour metastasis, which was
Figure 2 Immunoblotting analysis of nm23-H1 expression in the
tumourous (T) and nontumourous (N) tissue pairs from 10 patients with
OSCC. Extracts from tumour cells or normal oral mucosa derived from the
same patients were electrophoresed on a 12% polyacrylamide gel with
4.5% stacking gel. After transfer onto a nitrocellulose membrane, the
proteins were immunoblotted with 1:500 dilution of mouse monoclonal
antibodies specific to nm23-H1, followed by HRP-conjugated goat anti-
mouse IgG and development for enhanced chemiluminescence. Molecular
weight (in kDa) is shown on the right.
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yfrequently associated with poor prognosis. These data suggested
that nm23 could serve as a marker for disease progression and
prognosis in OSCC patients.
In the present study, we found that the positive rate of nm23-H1
expression was significantly higher in OSCCs at the late T stage
(T3, T4: tumour size 44cm) than the early stage. Similarly, it has
been indicated an association of nm23 overexpression with a larger
tumour in neuroblastoma, thyroid, gastric and renal cell carcino-
mas (Hailat et al, 1991; Zou et al, 1993; Park et al, 1995; Mu ¨ller
et al, 1998). Increasing evidences have suggested that nm23 be
Table 1 Relationship between nm23-H1 expression and clinicopathologic parameters (N¼86)
Expression of nm23-H1
Clinicopathologic parameter Number of patients Negative (%)
a Positive (%) P
b
Histologic grade of malignancy
Well-differentiated 50 25 (56.8) 25 (59.5) 0.972
Moderately differentiated 36 19 (43.2) 17 (40.5)
Tumour size
T1+T2 (p4cm) 54 33 (75.0) 21 (50.0) 0.030
T3+T4 (44cm) 32 11 (25.0) 21 (50.0)
Lymph node involvement
Negative 43 17 (38.6) 26 (61.9) 0.052
Positive 43 27 (61.4) 16 (38.1)
Distant metastasis
Negative 73 34 (77.3) 39 (92.9) 0.086
Positive 13 10 (22.7) 3 (7.1)
Tumour recurrence
Negative 57 27 (61.4) 30 (71.4) 0.448
Positive 29 17 (38.6) 12 (28.6)
Betel nut-chewing habit
Negative 36 21 (47.7) 15 (35.7) 0.363
Positive 50 23 (52.3) 27 (64.3)
Cigarette-smoking habit
Negative 25 8 (18.2) 17 (40.5) 0.042
Positive 61 36 (81.8) 25 (59.5)
aPercentage of patients in the category.
bw
2-test with Yates’ correction.
Table 2 Relationship between nm23-H1 expression and clinicopathologic parameters of patients with the early T-stage OSCC (N¼54)
nm23-H1
Clinicopathologic parameter Number of patients Negative (%)
a Positive (%) P
b
Histologic grade of malignancy
Well-differentiated 33 21 (63.6) 12 (57.1) 0.849
Moderately differentiated 21 12 (36.4) 9 (42.9)
Lymph node involvement
Negative 35 16 (48.5) 19 (90.5) 0.004
Positive 19 17 (51.5) 2 (9.5)
Distant metastasis
Negative 48 27 (81.2) 21 (100) 0.103
Positive 6 6 (18.2) 0 (0)
Tumour recurrence
Negative 41 22 (66.7) 19 (90.5) 0.095
Positive 13 11 (33.3) 2 (9.5)
Betel nut-chewing habit
Negative 29 18 (54.5) 11 (52.4) 1.000
Positive 25 15 (45.5) 10 (47.6)
Cigarette-smoking habit
Negative 15 5 (15.2) 10 (47.6) 0.022
Positive 39 28 (84.8) 11 (52.4)
aPercentage of patients in the category.
b w
2-test with Yates’ correction.
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yinvolved in cell growth and microtubule mitotic spindle poly-
meration in S phase (Igawa et al, 1994; Caligo et al, 1995). Cipollini
et al. (1997) also reported that downregulation of nm23 gene
inhibited cell proliferation. However, not all of the above studies
demonstrated a negative prognostic impact of nm23 overexpres-
sion or late T stage tumours (Zou et al, 1993; Mu ¨ller et al, 1998).
There were also some discrepancies among previous studies of the
same tumours, such as gastric and colorectal cancers (Cohn et al,
1991; Haut et al, 1991; Kodera et al, 1994; Mu ¨ller et al, 1998).
Concerning gastric cancers, Kodera et al (1994) reported that a
negative prognostic impact of decreased nm23 expression might
correlated with increased lymphatic metastasis; while Mu ¨ller et al
(1998) showed nm23 overexpression was associated with aggres-
sive tumour growth and poor survival. It is possible that nm23
could play variable roles in different molecular events and
contribute to distinct outcomes. These results certainly need
further investigations.
As noted previously, nm23, originally identified from a weakly
metastatic cancer cells, was found to have antimetastatic potential
in human carcinomas (Bevilacqua et al, 1989; Caligo et al, 1997).
Since clinical prognosis of OSCC patients is closely associated with
lymphatic spread and distant metastasis (Wang et al, 2002), it is
reasonable to hypothesise that nm23 may play some role in disease
progression of OSCC. Song et al, (2000) demonstrated that the
increase of nm23 expression correlated with decreased incidence
of lymph node metastasis in patients with head and neck cancers,
though Pavelic et al (2000) revealed a different result in patients
with the advanced disease. Such a variation may be due to
heterogeneity of primary tumour distribution, methods of
investigation and scoring systems for pathological variables. By
showing that patients with larger OSCCs (44cm) mostly have
nm23-H1 positive tumours, the current study indicated that nm23
might also be associated with cell proliferation (Caligo et al, 1995;
Cipollini et al, 1997). Many studies have reported that late-stage
cancer could obtain more metastatic ability by increasing events
contributing to tumor spreading, such as angiogenesis, adhesion,
proteolysis and motility (Petruzzelli et al, 1998; Bashyam, 2002).
To avoid such interference, that increased size of primary tumour
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Figure 3 Overall survival curves of patients at the early T-stage OSCC in
relation to tumour nm23-H1 expression. The survival analysis was assessed
by Kaplan–Meier method and the difference in survival between positive
and negative nm23-H1 expression groups was analysed by a log-rank test.
The positive nm23-H1 group had significantly better survival than the
negative nm23-H1 group (P¼0.014).
Table 3 Survival analysis of patients with OSCC (N¼84)
P
Clinicopathologic parameter (number
of patient analysed)
Univariate
analysis
Multivariate
analysis
Degree of differentiation
Well-differentiated (49) 0.321
Moderately (35)
Tumour size
T1+T2 (p4cm) (53) o0.001 0.002
T3+T4 (44cm) (31)
Lymph node involvement
Negative (42) o0.001 0.747
Positive (42)
Distant metastasis
Negative (71) o0.001 o0.001
Positive (13)
Tumour recurrence
Negative (55) o0.001 0.040
Positive (29)
Betel nut-chewing habit
Negative (36) 0.173
Positive (48)
Cigarette-smoking
Negative (25) 0.330
Positive (59)
nm23-H1 expression
Negative (43) 0.150
Positive (41)
Table 4 Survival analysis of patients with the early T-stage OSCC
(N¼53)
P
Clinicopathologic parameter (number
of patient analysed)
Univariate
analysis
Multivariate
analysis
Degree of differentiation
Well-differentiated (32) 0.443
Moderately (21)
Lymph node involvement
Negative (34) 0.015 0.911
Positive (19)
Distant metastasis
Negative (47) o0.001 0.013
Positive (6)
Tumour recurrence
Negative (40) 0.003 0.208
Positive (13)
Betel nut-chewing habit
Negative (29) 0.106
Positive (21)
Cigarette-smoking
Negative (15) 0.032 0.165
Positive (38)
nm23-H1 expression
Negative (32) 0.014 0.230
Positive (21)
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ycould escalate metastatic potential and then the data of patients at
the late T stage might confound statistical analyses, we therefore
particularly emphasised our analysis on patients at the early T
stage. Our results indicated that nm23-H1-negative OSCCs indeed
had a significantly higher incidence of lymph node metastasis at
the early T stage. However, such correlation was equivocal at the
late T stage (Table 1 and 2). These results suggested that the role of
nm23-H1 in OSCCs at early T stage, including carcinogenesis, be
different from that at late T stage, when the adjuvant therapy
should be applied (Bevilacqua et al, 1989; Caligo et al, 1997;
Cipollini et al, 1997; Pavelic et al,2 0 0 0 ;S o n get al,2 0 0 0 ) .A sg e n e t i c
instability altering with disease progression is one important
character of malignant tumour, it is possible that nm23-H1 play
various roles in the different stages of cancer development.
In fact, by an immunohistochemical study, Ohtsuki et al (1997)
had demonstrated that OSCCs with positive nm23 expression was
related with a lower incidence of lymph node metastasis. Lo Muzio
et al (1999) further showed that this nm23 was nm23-H1. Our
results supported their findings, in particular regarding patients at
the early T stage; these data clearly indicated that nm23-H1
expression could have antimetastatic potential and prognostic
significance in OSCC patients. Moreover, in addition to lymph
node involvement, we evaluated the correlations of nm23
expression with occurrence of distant metastasis. Although
statistical difference was not reached (P¼0.086), a marginally
higher metastatic incidence was observed in the nm23-H1 negative
group (22.7%, 10 out of 44) compared with that in the nm23-H1
positive group (7.1%, three out of 42). As a matter of fact that the
influence of nm23-H1 expression was clearly showed in the
univariate analysis on OSCC patients at the early T stage, in which
the survival of the nm23-H1 positive group was significantly better
than that of the negative group. However, we could not found the
similar result in patients at the advanced T stage. A larger study
cohort is required to conclusively determine the effect of nm23-H1
expression on lymph node involvement, distant metastasis and cell
proliferation, which may ultimately predict therapeutic response
and survival.
In our results, it is worth noting that cigarette smoking might
inhibit nm23-H1 expression and relate to poor survival for OSCC
patients at the early T stage by univariate analysis. This effect on
patients’ prognosis was not obvious in the multivariate analysis.
Our data indicated that smoking habit might be closely associated
with cancer development and metastasis at the early T stage, but
smoking alone was not a predicting factor for patients’ response to
adjuvant chemoradiotherapy at the late stage (Bundgaard et al,
1994). Furthermore, recent studies reported that mutagenicity of
tobacco smoke might have some influence on biologic behaviors of
OSCCs through DNA alterations, including K-ras oncogene and
p53 mutation (Westra et al, 1993; Hsieh et al, 2001). The
relationships between nm23-H1 expression and specific molecular
targets of tobacco carcinogens need more investigation.
Recently, an elegant study by Iizuka et al (2000) supported a
possibility by demonstrating that reduced nm23 expression could
increase cisplatin resistance. These authors showed that down-
regulation of nm23-H1 expression could decrease intracellular
cisplatin accumulation probably via altered Na
þ,K
þ-ATPase
activity. If, as suggested by the above data, the nm23-H1-
associated antimetastatic potential might be closely in company
with chemosensitivity; it is possible that less nm23-H1 expression
and hence higher cisplatin resistance may lead to poorer survival.
Previous literature reported that metastatic tumors seemed more
resistant to chemoradiotherapy (McKenna et al, 1990; Herbst and
Langer, 2002; Real et al, 2002) and it might result from the
common molecular mechanisms shared by both cancer metastasis
and chemoradioresistance. The lack of nm23 expression in cancer
cells might be another pathway leading to both events and has the
potential of being a clinically prognostic predictor for chemor-
adiotherapy. In our series, local irradiation and/or systemic
cisplatin-based chemotherapy were administered for the patients
with metastatic cancers over cervical lymph nodes or distant
organs. Referred to our database of OSCC patients, we will further
study the role of nm23 in chemoradiosensitivity.
Our results revealed that there was no relationship between
nm23-H1 expression and betel nut-chewing. A working group of
the International Agency for Research on Cancer (IARC)
concluded that evidence supporting a link between betel nut-
chewing alone and human oral cancer was not sufficient (IARC,
1986). Buccal cancers were reported more frequently found in
patients with betel nut-chewing habits (Thomas and MacLennan,
1992). However, tongue was only associated with cancers of
smokers and the most common site among patients without any
oral habits (Silverman and Griffith, 1972; Chen et al, 1999). In our
series, there were very few OSCC patients with betel nut-chewing
habit alone but without smoking (seven out of 86¼8%) and most
tumors were located on the tongue (58 out of 86¼67%). Previous
data reported that lingual cancers occurred less frequently in
patients with betel nut-chewing habit alone (Ko et al, 1995; Chen
et al, 1999). Furthermore, Taiwanese betel nuts do not contain
tobacco and are different from those in India, where betel nuts
nearly always include tobacco, a known cause of oral cancer. The
above observations may explain the result that there was no
significant relationship between nm23 H1 expression and the betel
nut-chewing habit in our study.
In conclusion, our results showed that nm23-H1 was frequently
expressed in pathologic specimens of OSCC. Nm23-H1 over-
expression correlated with larger primary tumour size. In patients
at the early T stage, increased nm23 expression was associated with
decreased incidence of lymph node involvement, which in turn
showed a better prognosis. This effect was suggested due to
antimetastatic potential and the role in chemoradiosensitivity of
nm23-H1. Nevertheless, other explanations are possible. The
mechanisms of nm23-H1 about cancer metastasis and cytotoxicity
of chemoradiation remain to be determined conclusively.
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